Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Deep Scientific Insights on trimetazidine hydrochloride's R&D Progress
27 October 2023
This article summarized the latest R&D progress of trimetazidine hydrochloride, the Mechanism of Action for trimetazidine hydrochloride, and the drug target R&D trends for trimetazidine hydrochloride.
Latest Hotspot
3 min read
Celltrion's Infliximab (subcutaneous formulation) receives FDA approval for the treatment of inflammatory bowel disease
27 October 2023
On Oct 25, 2023, Celltrion reported US FDA approval of Zymfentra (infliximab) for continued treatment of adult ulcerative colitis (UC) and Crohn's disease (CD) after intravenous infliximab treatment.
Drug Insights
5 min read
An In-depth Analysis of urapidil's R&D Progress and Mechanism of Action on Drug Target
27 October 2023
This article summarized the latest R&D progress of urapidil, the Mechanism of Action for urapidil, and the drug target R&D trends for urapidil.
Bio Sequence
3 min read
Biological Glossary | What is Attenuator?
27 October 2023
Attenuator in biotechnology refers to a nucleotide sequence in DNA that can lead to premature termination of transcription, a process found in bacteria and archaea.
Drug Insights
5 min read
Viltolarsen: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
27 October 2023
This article summarized the latest R&D progress of viltolarsen, the Mechanism of Action for viltolarsen, and the drug target R&D trends for viltolarsen.
Latest Hotspot
3 min read
Yasheng Pharmaceutical's Bcl-2/Bcl-xL dual-target inhibitor, APG-1252, releases its latest Phase 1b clinical trial data for the treatment of non-small cell lung cancer
26 October 2023
Yasheng Pharmaceutical presented updated clinical data for APG-1252 and Osimertinib to treat EGFR mutation lung cancer patients at the 2023 ESMO meeting on October 23, 2023.
Drug Insights
4 min read
Pharmaceutical Insights: tegafur's R&D Progress and its Mechanism of Action on Drug Target
26 October 2023
This article summarized the latest R&D progress of tegafur, the Mechanism of Action for tegafur, and the drug target R&D trends for tegafur.
Hot Spotlight
7 min read
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
26 October 2023
Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.
Drug Insights
5 min read
Exploring teniposide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
26 October 2023
This article summarized the latest R&D progress of teniposide, the Mechanism of Action for teniposide, and the drug target R&D trends for teniposide.
Latest Hotspot
3 min read
BioNova Pharmaceuticals' oral Menin inhibitor BN104 has received Fast Track designation from the FDA for the treatment of acute myeloid leukemia
26 October 2023
On October 24, 2023, BioNova Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to its product BN104 for the treatment of relapsed/refractory acute leukemia.
Drug Insights
4 min read
Decoding tenofovir alafenamide fumarate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
26 October 2023
This article summarized the latest R&D progress of tenofovir alafenamide fumarate, the Mechanism of Action for tenofovir alafenamide fumarate, and the drug target R&D trends for tenofovir alafenamide fumarate.
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of Nuclear Factor
26 October 2023
NF-κB is present in almost all animal cells and is a key transcription factor in various biological processes in the human body.